SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

a. Since December 31, 2023, the Company has collected approximately $0.3 million from expense reimbursements in connection with its collaboration with Chiesi, and approximately $4.6 million from sales to Pfizer.

b. In January 2024, the Company granted, with the approval of the Company’s compensation committee, 100,000 shares of restricted Common Stock, in the aggregate, to two of the Company’s employees under the Plan. The restricted stock vests over a three-year period in 12 equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $161,000.